Physician profile
Kris Michael Mahadeo
NPI 1922324672
$67,480.06
in general payments reported to CMS, 2019-2025
9 companies · $48K in 2025
The $48K reported for 2025 was more than what 97% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $2,975 · 2021: $237 · 2022: $267 · 2023: $16K · 2024: $35.39 · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $21K · Travel and Lodging: $11K · Food and Beverage: $1,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,576.00 |
| Consulting Fee | $20,960.00 |
| Travel and Lodging | $10,810.64 |
| Food and Beverage | $1,530.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $39,891.35 | 2025 | |
| Jazz Pharmaceuticals INC. | $10,289.67 | 2020-2023 | Defitelio |
| Vertex Pharmaceuticals Incorporated | $8,646.75 | 2022-2023 | |
| Gamida Cell INC. | $8,250.00 | 2025 | Aphexda |
| Novartis Pharmaceuticals Corporation | $284.54 | 2019-2024 | |
| Kite Pharma, INC. | $117.75 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kris Mahadeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.